Value Partners Investments Inc. Makes New Investment in Novo Nordisk A/S (NYSE:NVO)

Value Partners Investments Inc. acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 90,525 shares of the company's stock, valued at approximately $6,293,000. Novo Nordisk A/S comprises about 0.5% of Value Partners Investments Inc.'s investment portfolio, making the stock its 27th biggest position.

Other institutional investors also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL grew its position in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after purchasing an additional 300 shares during the last quarter. Park Square Financial Group LLC purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at about $29,000. Transce3nd LLC purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at about $33,000. Kelly Lawrence W & Associates Inc. CA purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at about $39,000. Finally, Mascagni Wealth Management Inc. purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at about $40,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on NVO. BNP Paribas began coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating on the stock. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Finally, Guggenheim downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Stock Performance

Shares of NVO traded up $0.80 on Friday, reaching $68.50. The company's stock had a trading volume of 5,624,379 shares, compared to its average volume of 7,221,599. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The stock has a market capitalization of $305.85 billion, a P/E ratio of 20.27, a PEG ratio of 1.21 and a beta of 0.66. The stock's 50 day simple moving average is $68.90 and its two-hundred day simple moving average is $77.56. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $145.99.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The company had revenue of $11.87 billion for the quarter. Research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.